PERCENTAGE RELEASE OF THE DRUG
INTRODUCTION
RELEASE KINETICS
Celecoxib is the Selective COX-2 nonsteroidal anti-inflammatory drug (NSAID)
GRAPH SHOWS
FIRST-ORDER
prescribed for osteoarthritis, rheumatoid arthritis, musculoskeletal pain, and
ankylosing spondylitis. Its therapeutic efficacy is impeded due to its low
bioavailability and aqueous solubility (5mg/L) and it is classified as BCS class II.
Celecoxib controlled released formulation is compulsory to extend the
therapeutic duration in arthritic conditions. A transdermal drug delivery system
is a better route than an oral one that utilizes a micro-emulsion system to
enhance celecoxib bioavailability through transdermal applied Nano-emulsion,
excelling commercial oral products. Introducing micro emulsion-based
hydrogel regulates drug release and enhances compliance by improving DDSOLVER DATA PROFILE
viscosity.
AIMS AND OBJECTIVES
To design micro emulsion-based hydrogel having celecoxib for transdermal
delivery
To develop a formulation that prolonged the bioavailability of Celecoxib
METHOD
DSC SPECTRA
FORMULATION DESIGN
CHARACTERIZATION DISCUSSION
Transdermal celecoxib micro-emulsion was developed using the Pseudo-ternary
POST-FORMULATION PRE-FORMULATION
FLOW CHART OF
phase diagram method. Pre-formulation studies indicated its suitability for a
transdermal drug delivery system. Appearance, pH, homogeneity, spreadability, and
drug content are upto the predetermined standards. This formulation revealed no
skin irritation effect. A linear standard curve of celecoxib formulation has appeared
on testing stipulating formulation content uniformity. Dissolution was performed
with the help of the Franz diffusion cell. Dissolution analysis performed by DDSolver
on these celecoxib formulations determines that all the formulation follows first
order. Differential Scanning Calorimetry (DSC) spectra established compatibility
between the drug and the excipients. The optimized formulation is best suited for
the Korsmeyer-Peppas model.
FLOW CHART OF
CONCLUSION
The development of the microemulsion-based hydrogel for transdermal delivery of
celecoxib drug in arthritic conditions provides an excellent approach to addressing
the limitation of conventional oral therapy by enhancing the bioavailability,
controlled release, and targeted drug delivery system. Through this design and
formulation a significant development in the field of transdermal drug delivery and
complete the aim of prolonging drug bioavailability.
RESULTS
PRE-FORMULATION
REFERENCES
RESULTS OF
Seok SH, Lee SA, Park ES. Formulation of a microemulsion-based hydrogel containing celecoxib.
Journal of Drug Delivery Science and Technology. 2018 Feb 1;43:409-14.
Subongkot T, Sirirak T. Development and skin penetration pathway evaluation of microemulsions for
enhancing the dermal delivery of celecoxib. Colloids and Surfaces B: Biointerfaces. 2020 Sep
1;193:111103.
POST-FORMULATION
Muzib YI, Sujitha YS, Ambedkar YR. Celecoxib Topical Nanoemulgel: Formulation, Ex-Vivo,
RESULTS OF
Pharmacodynamic, and Pharmacokinetic Studies. InProceedings of the 2nd International Conference
on Computational and Bio Engineering: CBE 2020 2021 (pp. 299-310). Springer Singapore.
Cao M, Ren L, Chen G. Formulation optimization and ex vivo and in vivo evaluation of celecoxib
microemulsion-based gel for transdermal delivery. AAPS pharmscitech. 2017 Aug;18:1960-71.
